Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

PsA patients had durable responses after 1 year of IV golimumab treatment

Publish date:: April 30, 2019

Key clinical point: The intravenous formulation of the TNF inhibitor golimumab produced durable responses and no new safety signals through 1 year of treatment in patients with active psoriatic arthritis.

Major finding: ACR20, ACR50, and ACR70 response rates in the golimumab group were 76.8%, 58.1%, and 38.6%, respectively, while in the crossover group, they were 77.0%, 53.6%, and 33.9%, respectively.

Study details: Follow-up report on the phase 3 GO-VIBRANT study of 480 adult patients with psoriatic arthritis.

Disclosures: The authors reported disclosures with AbbVie, Amgen, Bristol-Myers Squibb, Eli Lilly, Horizon, Janssen, Novartis, Pfizer, Sanofi, and UCB. Several authors reported current or former employment with Janssen Research & Development and stock or stock options in Johnson & Johnson.

Citation:

Husni ME et al. Arthritis Care Res. 2019 Apr 12. doi: 10.1002/acr.23905.

This Week's Must Reads

Osteoporosis prevalence in PsA similar to general population,

Swedish registry study finds atopic dermatitis significantly associated with autoimmune diseases,

Weight loss may be paramount lifestyle change in preventing gout,

Gut microbiome influences response to methotrexate in new-onset RA patients,

Early treatment of RA with DMARDs promotes sustained remission,